RxDoctor Payments Data

Paul Houston, MD

Family Medicine · Brazil, INNPI 1487622742

Payments from drug & device makers

$4,425in general payments, 2019–2025

Across 268 payments — averaging $16.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$587
  • Novo Nordisk$379
  • Novartis$368
  • Amgen$351
  • Lilly USA, LLC$315
  • Bayer$221
  • plus $2K from 40 others

What the payments were for

  • Food & beverage$4,39099%
  • Education$351%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,425 in reported general payments places this provider in the 85th percentile of 2,709 family medicine providers in Indiana.

See all family medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$173,633
Medicare patients
396
Services billed
7,514

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin245$297,187
FarxigaDapagliflozin Propanediol158$182,314
OzempicSemaglutide128$181,343
XareltoRivaroxaban142$148,646
EliquisApixaban126$143,636
TrulicityDulaglutide118$133,078
RybelsusSemaglutide70$121,346
Trelegy ElliptaFluticasone/Umeclidin/Vilanter101$103,298
EntrestoSacubitril/Valsartan77$88,671
EnbrelEtanercept11$83,369
MounjaroTirzepatide54$76,740
Gamunex-CImmune Globul G/Gly/Iga Avg 4612$57,393
MyrbetriqMirabegron60$49,818
LinzessLinaclotide45$48,156
Tresiba Flextouch U-100Insulin Degludec18$26,775

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Combivent Respimat, Glyxambi$22$334,180300 claims
Novo NordiskOzempic, Rybelsus$379$302,689198 claims
Lilly USA, LLCTrulicity, Mounjaro$315$209,818172 claims
AstraZenecaFarxiga$88$182,314158 claims
PfizerEliquis, Abrysvo$56$165,955197 claims
GSKTrelegy Ellipta, Shingrix, Breo Ellipta, Arnuity Ellipta$169$129,186195 claims
NovartisEntresto$368$88,67177 claims
AmgenEnbrel$351$83,36911 claims
AbbVieLinzess, Vraylar$587$66,56858 claims
MerckBelsomra$126$16,54336 claims
Esperion Therapeutics, Inc.Nexlizet$52$15,54017 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$15$5,294640 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,709 family medicine providers in Indiana.

Other family medicine in Brazil

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →